Logo image of AUGX

AUGMEDIX INC (AUGX) Stock Fundamental Analysis

NASDAQ:AUGX - Nasdaq - US05105P1075 - Common Stock - Currency: USD

2.35  0 (0%)

After market: 2.35 0 (0%)

Fundamental Rating

2

Taking everything into account, AUGX scores 2 out of 10 in our fundamental rating. AUGX was compared to 36 industry peers in the Health Care Technology industry. AUGX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AUGX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AUGX has reported negative net income.
In the past year AUGX has reported a negative cash flow from operations.
In the past 5 years AUGX always reported negative net income.
AUGX had a negative operating cash flow in each of the past 5 years.
AUGX Yearly Net Income VS EBIT VS OCF VS FCFAUGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of AUGX (-44.44%) is worse than 65.79% of its industry peers.
AUGX has a Return On Equity of -227.72%. This is amonst the worse of the industry: AUGX underperforms 81.58% of its industry peers.
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROIC N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AUGX Yearly ROA, ROE, ROICAUGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

AUGX has a Gross Margin of 48.21%. This is in the lower half of the industry: AUGX underperforms 60.53% of its industry peers.
AUGX's Gross Margin has improved in the last couple of years.
AUGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
AUGX Yearly Profit, Operating, Gross MarginsAUGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

2

2. Health

2.1 Basic Checks

AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AUGX has been increased compared to 1 year ago.
Compared to 5 years ago, AUGX has more shares outstanding
AUGX has a better debt/assets ratio than last year.
AUGX Yearly Shares OutstandingAUGX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AUGX Yearly Total Debt VS Total AssetsAUGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

AUGX has an Altman-Z score of -2.71. This is a bad value and indicates that AUGX is not financially healthy and even has some risk of bankruptcy.
AUGX has a worse Altman-Z score (-2.71) than 65.79% of its industry peers.
AUGX has a Debt/Equity ratio of 1.48. This is a high value indicating a heavy dependency on external financing.
AUGX has a Debt to Equity ratio of 1.48. This is amonst the worse of the industry: AUGX underperforms 84.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC9%
AUGX Yearly LT Debt VS Equity VS FCFAUGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

AUGX has a Current Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
AUGX has a Current ratio of 1.66. This is comparable to the rest of the industry: AUGX outperforms 47.37% of its industry peers.
AUGX has a Quick Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
AUGX has a Quick ratio (1.66) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
AUGX Yearly Current Assets VS Current LiabilitesAUGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.66% over the past year.
The Revenue has grown by 39.34% in the past year. This is a very strong growth!
The Revenue has been growing by 32.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%

3.2 Future

Based on estimates for the next years, AUGX will show a small growth in Earnings Per Share. The EPS will grow by 6.46% on average per year.
AUGX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.58% yearly.
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AUGX Yearly Revenue VS EstimatesAUGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
AUGX Yearly EPS VS EstimatesAUGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AUGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUGX Price Earnings VS Forward Price EarningsAUGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUGX Per share dataAUGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.76%
EPS Next 3Y6.46%

More info and screens

0

5. Dividend

5.1 Amount

AUGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUGMEDIX INC

NASDAQ:AUGX (10/1/2024, 8:00:01 PM)

After market: 2.35 0 (0%)

2.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)11-04 2024-11-04/bmo
Inst Owners72.68%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner Change0%
Market Cap116.16M
Analysts80
Price Target3.6 (53.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.41%
Max EPS beat(2)12.2%
EPS beat(4)4
Avg EPS beat(4)11.24%
Min EPS beat(4)4.41%
Max EPS beat(4)16.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-1.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)0.98%
Revenue beat(8)4
Avg Revenue beat(8)0.08%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 11.09
P/tB 11.09
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.21%
FCFM N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.82%
Cap/Sales 4.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -2.71
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)178.38%
Cap/Depr(5y)139.24%
Cap/Sales(3y)4.74%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
EBIT growth 1Y-14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.28%
EBIT Next 3Y9.53%
EBIT Next 5YN/A
FCF growth 1Y12.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.91%
OCF growth 3YN/A
OCF growth 5YN/A